Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
about
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expressionCOX-2: where are we in 2003?--distinction from NSAIDs becoming blurredCOX-2 and cancer: a new approach to an old problemThe bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.Diverse methyl sulfone-containing benzo[b]thiophene library via iodocyclization and palladium-catalyzed coupling.Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirinTopical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.Cyclooxygenase-2 inhibitors: promise or peril?Evaluation of etoricoxib in patients undergoing total knee replacement surgery in a double-blind, randomized controlled trialTolerance to etoricoxib in children with nonsteroidal anti-inflammatory drug hypersensitivityInvolvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats.Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis.Etoricoxib for arthritis and pain managementPharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the catEffect of β-sitosterol against methyl nitrosourea-induced mammary gland carcinoma in albino rats.Pharmacogenetics of analgesic drugsInhibition of Kv channel expression by NSAIDs depolarizes membrane potential and inhibits cell migration by disrupting calpain signalingDisruption of cyclooxygenase type 2 exacerbates apoptosis and renal damage during obstructive nephropathyEffects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo.Risk management profile of etoricoxib: an example of personalized medicineTreatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction.A receptor-grounded approach to teaching nonsteroidal antiinflammatory drug chemistry and structure-activity relationshipsOptimization of fast dissolving etoricoxib tablets prepared by sublimation technique.Depolarization and decreased surface expression of K+ channels contribute to NSAID-inhibition of intestinal restitution.Effect of etoricoxib on experimental oxidative testicular ischemia-reperfusion damage in rats induced with torsion-detorsion.Pharmacological characterisation of a rat model of incisional pain.Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.Treating acute gouty arthritis with selective COX 2 inhibitors.Ligand-free, palladacycle-facilitated Suzuki coupling of hindered 2-arylbenzothiazole derivatives yields potent and selective COX-2 inhibitors.Revisiting the systemic lipopolysaccharide mediated neuroinflammation: Appraising the effect of l-cysteine mediated hydrogen sulphide on it.Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practiceRobenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
P2860
Q24536027-9738ABFD-2897-480C-B97D-104FB9301BCAQ24536398-7EB8B405-0B7B-406D-9154-519BB1DEDADCQ24804373-4B84A69F-FD7E-40E1-8216-C4ADBF8B1580Q28191533-E2FA03B7-6868-4E81-B80C-A7FAF7276DB2Q28540582-9652ADB2-7484-48A2-AB15-5C7743ADDB88Q33393397-C59E680C-6F9D-4265-AC5D-9AE94462DABEQ33522431-61942EF3-ED27-4F1B-9575-F521A3705A4EQ33596397-1B36DCB3-AB16-4183-B604-BC17CD3AFB33Q33880198-A303EADC-8ABB-4C2C-B963-D818E76DD227Q33952053-CF50AB49-FBC3-4824-AD7C-DDD143BE17CFQ34322112-0B6D0DDC-47AB-4F15-9C92-FAB82B3A56D5Q35017693-CAA97306-C3C0-4522-9A2E-8FC0858AC04BQ35025780-443AF795-E3A1-4E01-A1D6-DD6DD7183BBDQ35037712-0E1E903E-97BA-4EB3-B3C0-2323146875AFQ35047037-5B4F8205-1551-4384-A020-40D940042B03Q35048654-972DE76B-8DA2-46DE-81F1-45C42B3D2E86Q35102135-22D6E4B2-707C-4078-8719-232BB905586EQ35166773-72F28C10-3ED5-4D0E-8725-A5342005E11EQ35545077-B3A4042A-2A74-4D2B-AD33-5214E92DD1FFQ36090487-88B2774B-2467-4CAA-B6D7-6905D0DF05CAQ36110592-7DAA1760-28BE-49DD-97B5-1973666CFFF2Q36307625-BF2A33CD-E775-4127-BE21-1D9FF6C6DECBQ36382109-D5BA6D65-0F7B-4E40-B7C5-E7ECAB19520DQ36790215-238445DF-065A-4DFD-8103-D59890EEDD2EQ37052864-B24DB459-CF98-4742-BACC-76F507A50157Q37437496-90D856DA-4545-46BD-B21F-BC07702C795BQ37692578-C9FB9261-B46A-4D88-9777-564B8C84F718Q39264038-1F8AFA62-0A1A-4DF8-A0E5-AAF4C8DAD48CQ39963047-4568193E-6B42-43B7-A84F-967884D65B72Q40133487-B499844B-DE45-49CD-9B15-5A690DE402F5Q41636189-DF9955FA-6E7B-4EC4-B709-5B73A1A8EC5EQ41820737-C61972E1-0186-4FF4-A95F-D379D9982B2DQ42010481-1EEC97ED-D932-4AB6-A242-33D5F38E1611Q42780423-6A9FE93E-4535-4C06-9A59-842F7F20100EQ49331211-F20F8CAE-58EF-4385-ADF1-127AF65C420EQ55402606-B94C470E-1F52-4A05-B771-15D8ED97D94FQ57072074-4DFCC370-3A1F-41CC-8F39-20A6EDA97101Q58777712-C1F6F2CC-E3EE-4DD1-9204-708C844F4CE3
P2860
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Etoricoxib (MK-0663): preclini ...... vely inhibit cyclooxygenase-2.
@ast
Etoricoxib (MK-0663): preclini ...... vely inhibit cyclooxygenase-2.
@en
type
label
Etoricoxib (MK-0663): preclini ...... vely inhibit cyclooxygenase-2.
@ast
Etoricoxib (MK-0663): preclini ...... vely inhibit cyclooxygenase-2.
@en
prefLabel
Etoricoxib (MK-0663): preclini ...... vely inhibit cyclooxygenase-2.
@ast
Etoricoxib (MK-0663): preclini ...... vely inhibit cyclooxygenase-2.
@en
P2093
P1476
Etoricoxib (MK-0663): preclini ...... ively inhibit cyclooxygenase-2
@en
P2093
A W Ford-Hutchinson
D Riendeau
I W Rodger
P304
P407
P577
2001-02-01T00:00:00Z